Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499459 | 0.90 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1MAPTGAANPSR1 | |
| SCHEMBL3309810 | 0.87 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL22686966 | 0.87 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1MAPTMAPK1AHR | |
| SCHEMBL24499463 | 0.83 | KMT2A (0.55) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL21686042 | 0.83 | MAPT (0.52) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL21765855 | 0.82 | HTT (0.72) | SMN1; SMN2ALDH1A1MAPTMAPK1AHR | |
| SCHEMBL2374142 | 0.82 | MEN1 (0.80) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL2914361 | 0.81 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1MAPTMAPK1AHR | |
| SCHEMBL21828753 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2AMEN1HTT | |
| SCHEMBL15754270 | 0.81 | LTB4R (0.64) | SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | PARABILIS MEDICINES, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2020041270-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | IAPP, VIP, NGLY1 | SMN1; SMN2 2559/4885ALDH1A1 4780/4885MAPT 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.